Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 4, 2006, Pages 1222-1227

  Chen, M ^a,b   Nafziger, A N ^a,b   Drusano, G L ^b   Ma, L ^b   Bertino Jr , J S ^a,b  

^a BASSETT RESEARCH INSTITUTE   (United States)

^b ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEM DERIVATIVE; ERTAPENEM;

ADULT; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BODY MASS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NONPARAMETRIC TEST; NORMAL HUMAN; OBESITY; PHARMACODYNAMICS; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; VOLUNTEER;

ADULT; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; BODY MASS INDEX; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OBESITY;

EID: 33645790070     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.50.4.1222-1227.2006     Document Type: Article

References (24)

1. Centers for Disease Control and Prevention. 2003. 1991-2001 prevalence of obesity among U.S. adults, by characteristics. Centers for Disease Control and Prevention, Atlanta, Ga. [Online.] http://www.cdc.gov/nccdphp/dnpa /obesity/trend/prev_char.htm.
2. Centers for Disease Control and Prevention. 2004. Prevalence of overweight and obesity among adults: United States, 1999-2002. Centers for Disease Control and Prevention, Atlanta, Ga. [Online.] http://www.cdc.gov/nchs /products/pubs/pubd/hestats/obese/obse99.htm.
3. Chiba, K., M. Tsuchiya, J. Kato, K. Ochi, Z. Kawa, and T. Ishizaki. 1989. Cefotiam disposition in markedly obese athlete patients, Japanese sumo wrestlers. Antimicrob. Agents Chemother. 33:1188-1192.
4. Curran, M., D. Simpson, and C. Perry. 2003. Ertapenem: a review of its use in the management of bacterial infections. Drugs 63:1855-1878.
5. D'Argenio, D. Z., and A. Schumitzky. 1997. ADAPT II user's guide: pharmacokinetic/pharmacodynamic systems analysis software. Biomedical Simulations Resource, Los Angeles, Calif.
6. Davis, R. L., R. W. Quenzer, H. P. Bozigian, and C. W. Warner. 1990. Pharmacokinetics of ranitidine in morbidly obese women. Ann. Pharmacother. 24:1040-1043.
7. Drusano, G. L. 2004. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug.' Nat. Rev. Microbiol. 2:289-300.
8. Forse, R. A., B. Karam, L. D. MacLean, and N. V. Christou. 1989. Antibiotic prophylaxis for surgery in morbidly obese patients. Surgery 106:750-756.
9. Jones, R. N., H. S. Sader, and T. R. Fritsche. 2005. Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms. Diagn. Microbiol. Infect. Dis. 52:71-74.
10. Leary, R., R. Jelliffe, A. Schumitzky, and M. Van Guilder. 2001. An adaptive grid, non-parametric approach to pharmacokinetic and dynamic (PK/PD) models, p. 389-394. In Proceedings of the 14th IEEE Symposium on Computer Based Medical Systems. IEEE Computer Society, Bethesda, Md.
11. Livermore, D. M., A. M. Sefton, and G. M. Scott. 2003. Properties and potential of ertapenem. J. Antimicrob. Chemother. 52:331-344.
12. Mann, H. J., and H. Buchwald. 1986. Cefamandole distribution in serum, adipose tissue, and wound drainage in morbidly obese patients. Drug Intell. Clin. Pharm. 20:869-873.
13. Musson, D. G., K. L. Birk, C. J. Kitchen, J. Zhang, J. Y. Hsieh, W. Fang, A. K. Majumdar, and J. D. Rogers. 2003. Assay methodology for the quantitation of unbound ertapenem, a new carbapenem antibiotic, in human plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 783:1-9.
14. National Institutes of Health. 1998. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. NIH publication 98-4083. National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Md. [Online.] http://www.nhlbi.nih .gov/guidelines/obesity/ob_gdlns.pdf. Accessed 2 August 2004.
15. Nix, D. E., A. K. Majumdar, and M. J. DiNubile. 2004. Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians. J. Antimicrob. Chemother. S3(Suppl. S2):ii23-ii28.
16. Odenholt, I. 2001. Ertapenem: a new carbapenem. Expert Opin. Investig. Drugs 10:1157-1166.
17. Reynolds, R., N. Potz, M. Colman, A. Williams, D. Livermore, and A. MacGowan. 2004. Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: the BSAC Bacteraemia Resistance Surveillance Programme. J. Antimicrob. Chemother. 53:1018-1032.
18. Salazar, D. E., and G. B. Corcoran. 1988. Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass. Am. J. Med. 84:1053-1060.
19. Shah, P. M., and R. D. Isaacs. 2003. Ertapenem. the first of a new group of carbapenems. J. Antimicrob. Chemother. 52:538-542.
20. Stokholm, K. H., J. Brochner-Mortensen, and P. F. Hoilund-Carlsen. 1980. Increased glomerular filtration rate and adrenocortical function in obese women. Int. J. Obes. 4:57-63.
21. Wexler, H. M. 2004. In vitro activity of ertapenem: review of recent studies. J. Antimicrob. Chemother. 53(Suppl. S2):ii11-ii21.
22. Wurtz, R., G. Itokazu, and K. Rodvold. 1997. Antimicrobial dosing in obese patients. Clin. Infect. Dis. 25:112-118.
23. Xuan, D., M. Banevicius, B. Capitano, M. K. Kim, C. Nightingale, and D. Nicolau. 2002. Pharmacodynamic assessment of ertapenem (MK-0826) against Streptococcus pneumoniae in a murine neutropenic thigh infection model. Antimicrob. Agents Chemother. 46:2990-2995.
24. Yost, R. L., and H. Derendorf. 1986. Disposition of cefotaxime and its desacetyl metabolite in morbidly obese male and female subjects. Ther. Drug Monit. 8:189-194.